-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
InnoModels: Introducing the Benefits of In Situ Surgical Models
Author:
InnoModels
Release time:
2024-03-08
In the journey of neuroscience, the deep understanding and effective treatment of brain diseases have been greatly challenged. As technology continues to advance, Biologically Accurate Surgical Models (BASM) have emerged to provide an unprecedented way to study the physiological and pathological processes of the brain, opening up new avenues for disease treatment. Below is a detailed description of the advantages of the InnoModels Biotechnology Accurate Surgical Models.
Highly Simulated Surgical Environment
One of the greatest advantages of the InnoModels Bio-In-Situ Surgical Model is its ability to simulate real surgical operations in a highly realistic environment. This model uses advanced biomaterials and technology to accurately replicate the anatomical structure and physiological functions of the brain, thus allowing researchers to perform a variety of delicate operations, such as tissue removal and vascular suturing, during simulated surgical procedures.
Real-time physiological feedback
Unlike traditional static models, the InnoModels Bio-In-Situ Surgical Model is able to provide real-time physiological feedback. This means that during simulated surgery, the model is able to mimic real brain responses such as bleeding, swelling and inflammatory responses. This real-time feedback allows researchers to more realistically assess surgical outcomes and risks to optimize surgical protocols.

Reduced experimental risk
Due to the high degree of simulation of the InnoModels Bioin situ surgical model, researchers can perform multiple surgical exercises and simulations on the model without the need to conduct experiments on real patients. This greatly reduces experimental risks and unnecessary injuries to patients, as well as providing valuable practice opportunities for physicians.
Facilitating drug development and therapeutic innovation
InnoModels' biologic in situ surgical models provide a powerful platform for drug discovery and therapeutic innovation. By simulating different disease states and surgical procedures, researchers can test the effects of different drugs and treatments to screen for the most effective treatment options. This provides strong support for therapeutic advances in neuroscience.
Promoting international cooperation and exchange
The standardization and reproducibility of the InnoModels Bioin situ surgical model makes international collaboration and exchange easier. Researchers from different countries and regions can conduct experiments using the same model, thus comparing and validating their respective research results. This helps to promote the overall progress and development of the field of neuroscience.
Wide Application Prospects
The InnoModels Bioin situ Surgical Model has a wide range of application prospects. It can be used not only to study the surgical treatment of neurological diseases such as tumors, vascular lesions, epilepsy, etc., but also to study the surgical intervention strategies for neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. In addition, with the continuous advancement of technology, this model is expected to play an important role in the fields of neuroregenerative medicine and neuroengineering.
In conclusion, the in-situ surgical model of InnoModels Biotechnology has become a major breakthrough in the field of neuroscience research due to its advantages of high simulation, real-time physiological feedback, reduction of experimental risk, facilitation of drug development and therapeutic innovation, as well as a wide range of application prospects. With the continuous development and improvement of this technology, we have reason to believe that it will play an even more important role in future neuroscience research.
Previous Page
Previous Page
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd